Bristol Myers Squibb : Q4 2022 Results Presentation (with Appendix)

Q4 2022 Results

February 2, 2023

Forward Looking Statements and Non-GAAP Financial Information

This presentation contains statements about Bristol-Myers Squibb Company's (the "Company") future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to, (i) new laws and regulations, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company's most recent annual report on Form 10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and Exchange Commission's website, on the Company's website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed.

In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise.

This presentation includes certain non-generally accepted accounting principles ("GAAP") financial measures that we use to describe the Company's performance. The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Company's financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company's baseline performance, supplement or enhance management's, analysts' and investors' overall understanding of the Company's underlying financial performance and trends and facilitate comparisons among current, past and future periods. This presentation also provides certain revenues and expenses excluding the impact of foreign exchange ("Ex-FX"). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.

The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable financial measure are available on our website at www.bms.com/investors.

Also note that a reconciliation of forward-lookingnon-GAAP operating margin is not provided because a comparable GAAP measure is not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of the unwind of inventory purchase price adjustments, accelerated depreciation and impairment of property, plant and equipment and intangible assets, and stock compensation resulting from acquisition-related equity awards, or currency exchange rates. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.

Q4 2022 Results

Not for Product Promotional Use

2

Giovanni Caforio, MD

Chairman of the Board

and Chief Executive Officer

in-line YoY; +3% Ex-FX*

(5%) YoY; (1%) Ex-FX*

Q4 & Full Year 2022 Performance

Strong Commercial Execution

Global Net Sales

Q4:~$11.4B

FY:~$46.2B

In-Line Brands & New Product Portfolio:

Q4:~$9.0B +7% YoY; +12% Ex-FX* FY:~$35.4B +9% YoY; +13% Ex-FX

Strong Financial Execution

Earnings Per Share (EPS)

Q4: GAAP $0.95, (11%) YoY

Non-GAAP* $1.82, (1%) YoY

FY: GAAP $2.95, (5%) YoY;

Non-GAAP* $7.70, +8% YoY

2023 Guidance

*

3 first-in-class medicines launched in 2022

Total Sales

~2% YoY Growth1

GAAP EPS* Non-GAAP EPS*

$4.03 - $4.33 $7.95 - $8.25

Reflects continued top & bottom-line growth

Q4 2022 Results	*See "Forward-Looking Statements and Non-GAAP Financial Information"	Not for Product Promotional Use	4
1Sales growth on reported & ex-FX basis

Delivered on Our Commitments

Key Milestones in 2022

Opdivo (+/- Yervoy)

Opdualag

bempeg

Breyanzi

Abecma

iberdomide

U.S./EU expected approvals:

1L ESCC (CM-648)

Neo-adj lung EFS (CM-816) (U.S.)

• Adj. RCC (CM-914)

1L melanoma U.S. approval

1L melanoma EU approval Initiation 2L+ CRC Ph3

• 1L melanoma
• 1L renal
• 1L bladder
• Neo-adj.cis-ineligible MIBC

2L LBCL U.S. approval 3L+ LBCL EU approval

2L+ MM Ph2 (KarMMa-2)3L-5L MM Ph3 (KarMMa-3)

Initiation 2L+ MM Ph3 (EXCALIBER)

Reblozyl

mezigdomide

Sotyktu

cendakimab

Camzyos

milvexian

1L MDS Ph3 (COMMANDS)

4L+ MM Ph1/2

Initiation triplet 2L+ MM Ph3

PsO U.S. approval

SLE Ph2

AD Ph21

oHCM U.S. approval

oHCM Ph3 (VALOR)

Initiation nHCM Ph3 (ODYSSEY- HCM)

SSP Ph2

Q4 2022 Results	Milestones represent data readouts unless otherwise specified	Not for Product Promotional Use	5
To be expanded to include regulatory milestones pending future registrational successes

1Met primary endpoint; no plan to move to registrational trials